Quick Facts
  • Primary Location:
    Fox Chase Cancer Center
  • Expertise:
    Molecular Therapeutics
    Immunotherapy
  • Speciality:
    Oncology/Hematology
  • Gender:
    Male
  • Language:
    English
  • Med School:
    Philadelphia College of Osteopathic Medicine

Get to Know Dr. Hossein Borghaei

Thoracic oncologist Dr. Hossein Borghaei specializes in the treatment of lung cancer, malignant mesothelioma and endobronchial disease at the Fox Chase Cancer Center in Philadelphia.

He believes strongly in personalizing therapy, using a patient’s cancer type and genetics, along with their personal, social and family needs, in formulating an individualized treatment plan.

“I believe that we treat more than just a disease,” he said. “I consider the patient as a whole, an individual with a disease, and not just the disease. I believe in engaging patients and their families in their care to the extent that my patients allow it.”

Borghaei uses a multidisciplinary approach that includes the latest immunotherapies, along with potential surgical and radiological interventions for his patients. He is an active researcher with a deep interest in advancing treatment for mesothelioma and other malignancies.

He serves as chief in the Division of Thoracic Medical Oncology and co-director of the Immune Monitoring Facility at Fox Chase. He also is part of the Lung Cancer and Mesothelioma Translational Research Disease Group.

Contact Hossein Borghaei
Mesothelioma specialist speaking with a patient and his wife
Get the Best Treatment
Get help connecting with Dr. Borghaei and find the treatment that’s best for you.

Specialties of Dr. Hossein Borghaei

Dr. Hossein Borghaei’s Experience and Education

  • Fox Chase Cancer Center
  • Fox Chase Cancer Center, Hematology-Oncology (Fellowship)
  • Graduate Hospital, Philadelphia (Residency)
  • Philadelphia College of Osteopathic Medicine (D.O.)

Awards and Certifications

  • American Board of Internal Medicine
  • National Board of Osteopathic Medical Examiners
  • Medical Oncology
  • American Society of Clinical Oncology
  • American Association of Cancer Research
  • National Comprehensive Cancer Network, Pleural Mesothelioma/Thymomas Committee

Publications of Dr. Hossein Borghaei

  • Borghaei, H. et al. (2019, January 14). 24-Month Overall Survival from KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin with or without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous Non-Small Cell Lung Cancer. Journal of Thoracic Oncology.
  • Borghaei, H. et al. (2015, October 22). Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. New England Journal of Medicine.
  • Moran, T. et al. (2014, November 7). Activity of dalotuzumab, a selective anti-IGF1R antibody, in combination with erlotinib in unselected patients with Non-small-cell lung cancer: a phase I/II randomized trial. Experimental Hematology & Oncology.
  • Borghaei, H. et al. (2009, September 1). Phase I dose escalation, pharmacokinetic and pharmacodynamic study of naptumomab estafenatox alone in patients with advanced cancer and with docetaxel in patients with advanced non-small-cell lung cancer. Journal of Clinical Oncology.

Lab technician using a microscope in a lab
COVID-19 and Mesothelioma Presentation
United States one-hundred-dollar bills
Access More than $32 Billion in Trust Funds
Technician documenting notes in a lab
Find Active Mesothelioma Clinical Trials

  •  
  •  
  •  
Tell us what you think
Did this article help you?
How did this article help you?
What about this article isn’t helpful for you?
Did this article help you?

Thank you for your feedback. Would you like to speak with a Patient Advocate?